Emergent Biosolutions (NYSE:EBS) Announces Earnings Results

Emergent Biosolutions (NYSE:EBS) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.54), FiscalAI reports. Emergent Biosolutions had a return on equity of 20.85% and a net margin of 9.62%.The firm had revenue of $148.70 million for the quarter, compared to analysts’ expectations of $217.50 million.

Emergent Biosolutions Trading Up 1.0%

NYSE EBS traded up $0.11 during trading on Thursday, hitting $11.12. The stock had a trading volume of 1,304,874 shares, compared to its average volume of 820,171. The company has a quick ratio of 3.15, a current ratio of 5.76 and a debt-to-equity ratio of 1.14. The company has a market capitalization of $584.02 million, a PE ratio of 8.55 and a beta of 2.35. The firm has a 50 day moving average price of $11.79 and a 200 day moving average price of $10.39. Emergent Biosolutions has a twelve month low of $4.02 and a twelve month high of $14.06.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on EBS. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Emergent Biosolutions in a research report on Monday, December 29th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Emergent Biosolutions in a research note on Tuesday, December 16th. Finally, Wall Street Zen raised Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 30th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $15.00.

Insider Activity at Emergent Biosolutions

In related news, Director Ronald Richard sold 21,984 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the completion of the transaction, the director owned 98,417 shares in the company, valued at approximately $1,178,051.49. The trade was a 18.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Emergent Biosolutions

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. grew its holdings in shares of Emergent Biosolutions by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 78,945 shares of the biopharmaceutical company’s stock worth $976,000 after purchasing an additional 1,764 shares during the last quarter. Deutsche Bank AG grew its position in shares of Emergent Biosolutions by 1.1% during the fourth quarter. Deutsche Bank AG now owns 181,744 shares of the biopharmaceutical company’s stock worth $2,246,000 after acquiring an additional 1,941 shares during the last quarter. Mariner LLC raised its position in Emergent Biosolutions by 18.4% in the 4th quarter. Mariner LLC now owns 21,274 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 3,307 shares during the last quarter. Cetera Investment Advisers boosted its stake in Emergent Biosolutions by 1.6% during the 4th quarter. Cetera Investment Advisers now owns 219,483 shares of the biopharmaceutical company’s stock worth $2,713,000 after purchasing an additional 3,489 shares during the period. Finally, CANADA LIFE ASSURANCE Co acquired a new stake in shares of Emergent Biosolutions during the fourth quarter worth about $45,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.